Article
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2018
Dickler Maura N, Saura Cristina, Richards Donald A, Krop Ian E, Cervantes Andrés, Bedard Philippe L, Patel Manish R, Pusztai Lajos, Oliveira Mafalda, Cardenas Alison K, Cui Na, Wilson Timothy R, Stout Thomas J, Wei Michael C, Hsu Jerry Y, Baselga José
Abstract excerpt
Purpose: This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer.Patients and Methods: Patients received 6-mg oral taselisib capsules daily plus intramuscular fulvestrant (500 mg) until disease progression or unacceptable toxicity....
Topics
Join the communities discussing this publication.